Drugs / [123I]ioflupane
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04564092 | May → Sep 2021 | — | GE Healthcare | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-11-03 | GE Healthcare | Regulatory DATSCAN™ (Ioflupane I 123 Injection) indication expanded to include use in patients with suspected Dementia with Lewy Bodies (DLB) gehealthcare.com ↗
DaTscan has been approved by the U.S. Food and Drug Administration (FDA) for use in patients with suspected Dementia with Lewy Bodies (DLB). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-11-03 | GE Healthcare | DATSCAN™ (Ioflupane I 123 Injection) indication expanded to include use in patients with suspected Dementia with Lewy Bodies (DLB) gehealthcare.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [123I]ioflupane | “[123I]ioflupane is a radiopharmaceutical used to visualise the dopaminergic neuron terminals in the striata, to aid in the differential diagnosis among Parkinsonian syndromes...” PMID 37029298 ↗ Apr 2023 |
| Known as | DaTSCAN | “DaTSCAN™ Ioflupane (123I) Injection” NCT04564092 ↗ |
| Modality | Diagnostic / imaging agent | “[123I]ioflupane is a radiopharmaceutical used to visualise the dopaminergic neuron terminals in the striata” PMID 37029298 ↗ Apr 2023 |
| Route | Intravenous | “by bolus IV injection” NCT04564092 ↗ |